License Agreements, Strategic Partnerships, Regulatory Approvals, Acquisitions and Sale of Senior Notes - Research Report on Johnson & Johnson, Amgen, Gilead, MAKO, and Edwards Lifesciences

Tue Oct 1, 2013 8:00am EDT

* Reuters is not responsible for the content in this press release.

License Agreements, Strategic Partnerships, Regulatory Approvals, Acquisitions and Sale of Senior Notes - Research Report on Johnson & Johnson, Amgen, Gilead, MAKO, and Edwards Lifesciences

PR Newswire

NEW YORK, October 1, 2013 /PRNewswire/ --

Editor Note: For more information about this release, please scroll to bottom.

Today, Analysts' Corner announced new research reports highlighting Johnson & Johnson (NYSE: JNJ), Amgen, Inc. (NASDAQ: AMGN), Gilead Sciences, Inc. (NASDAQ: GILD), MAKO Surgical Corp. (NASDAQ: MAKO), and Edwards Lifesciences Corp. (NYSE: EW). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.

Johnson & Johnson Research Report

On September 25, 2013, Janssen R&D Ireland (Janssen R&D), a part of the Janssen Pharmaceutical Companies of Johnson & Johnson, announced that it has signed a license agreement with PATH for the development of the human immunodeficiency virus type 1 (HIV-1) medicine rilpivirine in a long-acting injection (depot formulation) as potential pre-exposure prophylaxis (PrEP) against HIV infection. Janssen R&D stated that under the terms of the agreement, a Drug Development program of PATH (an international nonprofit organization that transforms global health through innovation) has the right to develop rilpivirine long-acting formulation as a new way to prevent HIV infection. In addition, the Company said that PATH intends to conduct prophylaxis clinical trials in collaboration with partners including the HIV Prevention Trials Network. PATH and Janssen will evaluate entering into a late stage development agreement covering the use of rilpivirine as PrEP for uninfected individuals at risk of acquiring HIV, after the completion of clinical Phase 2 program. The Full Research Report on Johnson & Johnson - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.analystscorner.com/r/full_research_report/07a8_JNJ]

--

Amgen, Inc. Research Report

On September 24, 2013, Amgen, Inc. (Amgen) and ShanghaiTech University announced a memorandum of understanding (MOU) to form a strategic partnership for the advancement of biopharmaceutical discovery and translational research in China. Amgen stated that under the terms of the MOU, it will co-locate its China R&D center with ShanghaiTech University's two life sciences institutes- the Shanghai Institute for Advanced Immunochemical Studies (SIAIS) and the iHuman Institute. Sean E. Harper, M.D., Executive Vice President of R&D at Amgen, said, "Amgen and ShanghaiTech University share mutual goals of scientific excellence and rigor and will benefit from each other's strength and expertise in advancing biopharmaceutical discovery in China. Expansion into China is a business priority for Amgen and opening this R&D center is another clear and important step forward in Amgen's commitment to the China market." Further, the Company stated that it expects its China R&D center to be fully operational in 2014. The Full Research Report on Amgen, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.analystscorner.com/r/full_research_report/e96b_AMGN]

--

Gilead Sciences, Inc. Research Report

On September 25, 2013, Gilead Sciences Inc. (Gilead) announced that the European Commission has granted marketing authorization for once-daily Tybost (cobicistat 150mg tablets) - a pharmacokinetic enhancer that boosts blood levels of certain HIV medicines. The Company stated that Tybost is indicated as a boosting agent for the HIV protease inhibitors atazanavir 300 mg once daily and darunavir 800 mg once daily as part of antiretroviral combination therapy in adults with HIV-1 infection. Norbert Bischofberger, PhD, Executive Vice President, Research and Development and Chief Scientific Officer of Gilead, said, "Gilead is pleased to offer HIV patients who rely on protease inhibitors a new boosting option to help facilitate once-daily dosing - an important factor in supporting treatment adherence."  According to the Company, the aforesaid approval from the European Commission permits Gilead to market Tybost in all 28 countries of the European Union. The Full Research Report on Gilead Sciences, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.analystscorner.com/r/full_research_report/9898_GILD]

--

MAKO Surgical Corp. Research Report

On September 25, 2013, MAKO Surgical Corp. (MAKO) announced a definitive agreement with Stryker Corporation (Stryker), under which Stryker will acquire all the outstanding shares of MAKO for $30.00 per share in cash, for an aggregate purchase price of c.$1.7 billion. According to the Company, the transaction is subject to customary closing conditions, including approval from the MAKO stockholders. Kevin A. Lobo, President and CEO of MAKO, said, "The acquisition of MAKO combined with Stryker's strong history in joint reconstruction, capital equipment (operating room integration and surgical navigation) and surgical instruments will help further advance the growth of robotic assisted surgery. Our combined expertise offers the potential to simplify joint reconstruction procedures, reduce variability and enhance the surgeon and patient experience. We look forward to welcoming the MAKO team to Stryker." The Full Research Report on MAKO Surgical Corp. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.analystscorner.com/r/full_research_report/7465_MAKO]

--

Edwards Lifesciences Corp. Research Report

On September 24, 2013, Edwards Lifesciences Corp. (Edwards Lifesciences) announced that the Company has agreed to sell $600 million aggregate principal amount of 2.88% senior unsecured notes due October 15, 2018 at a price equal to 99.5% of the principal. The Company informed that the sale of the senior notes is expected to close on October 3, 2013, subject to customary closing conditions. According to Edwards Lifesciences, it intends to use the net proceeds from the offering to repay amounts outstanding under its revolving credit facility and any remaining proceeds for general corporate purposes. The Full Research Report on Edwards Lifesciences Corp. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.analystscorner.com/r/full_research_report/48b8_EW]

----

EDITOR NOTES:

  1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.
  2. Information in this release is fact checked and produced on a best efforts basis and reviewed by Ananya Ghosh, a CFA charterholder. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
  3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
  4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco@EquityNewsNetwork.com.
  5. For any urgent concerns or inquiries, please contact us at compliance@EquityNewsNetwork.com.
  6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research@EquityNewsNetwork.com for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider represented by Ananya Ghosh, CFA, has only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE Analysts' Corner

Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.